Autres langues Zai Lab Limited Deutsche Boerse AG

Actions

1ZL

US98887Q1040

Produits pharmaceutiques

Temps réel estimé 09:27:51 10/09/2026 Varia. 5j. Varia. 1 janv.
20,70 EUR -3,27 % Graphique intraday de Zai Lab Limited -7,14 % +42,47 %

Autres langues

04/09 Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Friday Trading
02/09 Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
31/08 Asian Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading
28/08 Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up 2% for Week
26/08 Zai Lab's Net Loss Widens 14% in H1, Revenue Drops 6%
25/08 Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
19/08 Asian Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday Trading
17/08 Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
17/08 Zai Lab Limited and Argenx Announces Positive Topline Results From Phase 3 Alkivia Trial Of Efgartigimod In Autoimmune Myositis
13/08 Asian Equities Traded in the US as American Depositary Receipts Marginally Higher in Thursday Trading
11/08 Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading
07/08 Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; End Week Up 2%
06/08 Asian Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
06/08 Zai Lab Shares Rise After Q2 Beat
06/08 Zai Lab Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08 Earnings Flash (ZLAB) Zai Lab Limited Reports Q2 Revenue $106.3M, vs. FactSet Est of $103.9M
06/08 Earnings Flash (ZLAB) Zai Lab Limited Reports Q2 Loss of $0.46 per ADS, vs. FactSet Est of $-0.68
06/08 Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
03/08 Zai Lab Receives FDA Orphan Drug Designation for Zocilurtatug Pelitecan in Neuroendocrine Carcinomas
03/08 U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
29/07 Asian Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading
22/07 Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
29/06 Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing
17/06 Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan in Pulmonary Neuroendocrine Carcinomas
16/06 Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug
Aucun résultat pour cette recherche
-40% : Les Meilleurs Outils Réservés aux Abonnés pour Identifier les Meilleurs Investissements de Demain !
j
:
:
PROFITEZ-EN MAINTENANT
🔇